ABBV AbbVie Inc.

64.43
+1.45  (+2%)
Previous Close 62.98
Open 63.51
Price To Book -11.13
Market Cap 95,258,713,682
Shares 1,478,483,838
Volume 8,348,143
Short Ratio 4.12
Av. Daily Volume 11,820,094

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
Risankizumab
Ulcerative colitis
Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Depatuxizumab mafodotin ABT-414
Glioblastoma (rGBM)
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in 2021.
Venetoclax - CANOVA
Relapsed or refractory multiple myeloma
Phase 3 trial planned.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial planned.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2H 2017.
Risankizumab
Crohn’s Disease
FDA approval announced April 23, 2019.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 3 trial planned for 2018.
Risankizumab
Psoriatic Arthritis
Phase 3 trial initiated late 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
NDA filing announced August 5, 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
FDA Approval announced August 16, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 data due 2020.
Rova-T (MERU)
First-line Small Cell Lung Cancer
FDA approval announced January 28, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3 primary endpoint not met (PFS/OS).
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2H 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
sNDA filing announced June 4, 2019.
Venetoclax and obinutuzumab
Chronic lymphocytic leukemia